Human genetics implicate thromboembolism in the pathogenesis of long COVID in individuals of European ancestry

Art Schuermans1,2,3, Andreas Verstraete4,5, Vilma Lammi6,7

  • 1KU Leuven Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, Leuven, Belgium. aschuerm@broadinstitute.org.

PubMed

Insights

Genetic links between blood clots (thromboembolism) and long COVID provide new insights into the condition

Area of Science:

  • Genetics
  • Immunology
  • Infectious Diseases

Background:

  • Long COVID presents with diverse post-acute symptoms affecting multiple organs.
  • Mechanisms for long COVID, such as inflammation and thromboembolism, lack robust human evidence.
  • Causal links between SARS-CoV-2 infection and long COVID pathogenesis remain unclear.

Purpose of the Study:

  • To investigate the association between genetic variants related to thromboembolism and the risk of developing long COVID.
  • To identify potential molecular pathways contributing to long COVID through genetic analysis.

Main Methods:

  • Utilized data from the Long COVID Host Genetics Initiative (3,018 cases, 994,582 controls).
  • Employed Mendelian randomization to assess the causal effect of genetically predicted venous thromboembolism risk on long COVID.
  • Conducted downstream analyses using gene-specific instruments and expression data.

Main Results:

  • Increased genetically predicted venous thromboembolism risk was significantly associated with higher odds of long COVID (OR=1.21).
  • This association remained independent of acute COVID-19 severity and was confirmed in external datasets.
  • Protease-activated receptor 1 (PAR-1) was identified as a potential molecular contributor.

Conclusions:

  • Human genetic evidence supports shared pathogenetic pathways between thromboembolism and long COVID.
  • Findings suggest that thromboembolic processes may play a role in the development of long COVID.
  • Identifies PAR-1 as a potential therapeutic target for long COVID.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
294
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.9K
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
17.8K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
15.2K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
270